Piper Sandler Boosts Becton, Dickinson and Company (NYSE:BDX) Price Target to $280.00
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) had its target price hoisted by analysts at Piper Sandler from $275.00 to $280.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock.
Becton, Dickinson and Company announced it repurchased $750M in BD stock to date in FY25. In addition, the board has authorized the company to ...
After UnitedHealthcare CEO Brian Thompson was shot to death in December, law enforcement records show a burst of police ...
This was the stock's third consecutive day of gains.
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) announced that its board has authorized a share buyback program on ...
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, ...
In a notable performance, Becton Dickinson and Co. (NYSE:BDX) stock achieved a 52-week high, reaching a price level of ...
Company will spotlight sustainable solutions to enhance patient safety, workforce well-being, and care delivery efficiency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback